DUPIXENT was studied in 3 clinical trials with more than 2,100 adults with uncontrolled moderate-to-severe eczema (atopic dermatitis).
Results from two 16-week adult clinical trials with DUPIXENT when used alone compared to adult patients not taking DUPIXENT
The most common side effects in adult patients were injection site reactions, eye and eyelid inflammation, including redness, swelling, and itching, and cold sores in your mouth or on your lips.
In clinical trials for adults, clearer skin was seen. Use the slider to view these before
and after results with 16 weeks of treatment with DUPIXENT.
Real patients shown. Additional factors (including possible use of other treatments) may have impacted results. Individual results may vary.
Expand the boxes below to see more detailed results from the 3 DUPIXENT clinical studies with adults.
Results at 16 weeks when DUPIXENT was used alone*† compared to adult patients not taking DUPIXENT
48% of adult patients showed a 75% improvement in their skin compared to 13% not taking DUPIXENT
37% of adult patients had clear or almost clear skin compared to 9% not taking DUPIXENT
33% of adult patients showed a 90% improvement in their skin compared to 7% not taking DUPIXENT
*Results from "DUPIXENT alone" represents the average results from 2 studies
†All patients used a daily moisturizer
Results at 16 weeks when DUPIXENT was used every other week with topical corticosteroids compared to adult patients taking topical corticosteroids only
39% of adult patients had clear or almost clear skin when DUPIXENT was used with topical corticosteroids compared to 12% on topical corticosteroids only
69% of adult patients showed a 75% improvement in their skin when DUPIXENT was used with topical corticosteroids compared to 23% on topical corticosteroids only
40% of adult patients showed a 90% improvement in their skin when DUPIXENT was used with topical corticosteroids compared to 11% on topical corticosteroids only
Adult patients experienced a significant itch reduction as defined within the clinical trials
38% of adult patients had significant itch reduction at 16 weeks when DUPIXENT was used alone compared to 11% not taking DUPIXENT
59% of adult patients had significant itch reduction at 16 weeks when DUPIXENT was used with topical corticosteroids compared to 20% on topical corticosteroids only
Results represent the average results of 2 studies
The majority of adult patients saw significant skin improvement and itch reduction at 1 year of treatment with DUPIXENT when used with topical corticosteroids.
These results show the percentage of adult patients who experienced the following results at 1 year (52 weeks) while taking DUPIXENT once every other week while using topical corticosteroids compared to patients on topical corticosteroids only.
36% of adult patients had clear or almost clear skin when DUPIXENT was used with topical corticosteroids compared to 13% on topical corticosteroids only
65% of adult patients saw a 75% improvement in their skin when DUPIXENT was used with topical corticosteroids compared to 22% on topical corticosteroids only
51% of adult patients had significant itch reduction at 1 year when DUPIXENT was used with topical corticosteroids compared to 13% on topical corticosteroids only
The safety profile of DUPIXENT used with topical corticosteroids through Week 52 in adults was generally consistent with the safety profile observed at Week 16.
Use this Healthgrades™ tool to easily find nearby specialists with experience in treating children, teens, and adults with uncontrolled moderate-to-severe eczema (atopic dermatitis).
Our goal is for you to get the most out of your visit to the doctor. Download the discussion guide for tips on how to have a productive conversation.
See the Doctor Discussion GuideSubscribe for updates to get the latest news and information about DUPIXENT.
You'll receive the latest information in your email.
If you've been prescribed DUPIXENT, you can enroll in DUPIXENT MyWay with your doctor and get access to support resources like a personal Nurse Educator, supplemental injection support, and more.
